Rody A, Karn T, Solbach C, Gaetje R, Munnes M, Kissler S, Ruckhäberle E, Minckwitz G V, Loibl S, Holtrich U, Kaufmann M
Department of Obstetrics and Gynecology, J. W. Goethe-University, Frankfurt, Germany.
Breast. 2007 Jun;16(3):235-40. doi: 10.1016/j.breast.2007.02.006. Epub 2007 Apr 20.
Gene expression profiling using Affymetrix HG-U133 Arrays (22,500 genes) was performed on fresh frozen pretherapeutic core biopsies from 50 patients undergoing neoadjuvant chemotherapy (NAC) with docetaxel, adriamycin, cyclophosphamide (TAC) within the GEPARTRIO trial. The Sorlie classification based on the "intrinsic gene set" revealed four different subgroups in our cohort (normal-like: 14%, basal-like: 20%, erbB2+: 22% and luminal: 44%), which is in line with the original description. High genomic grade but not histopathological grading was statistically different within the four subgroups (P<0.001). About 45.5% of tumors classified according to erbB2+ cluster showed a pathological complete response compared to 0% in the normal-like, 10.0% in the basal-like and 9.1% in the luminal subgroup (P=0.024). There was a trend to less tumor relapses in the erbB2+ subgroup (0%) compared to the normal-like (28.6%), basal-like (30.0%) and luminal (13.6%) cluster (P=0.215). Our data suggest that the molecular tumor subtypes based on the "intrinsic gene set" can be used to predict tumor response according to NAC.
在GEPARTRIO试验中，对50例接受多西他赛、阿霉素、环磷酰胺（TAC）新辅助化疗（NAC）的患者新鲜冷冻的治疗前核心活检组织进行了使用Affymetrix HG-U133芯片（22,500个基因）的基因表达谱分析。基于“内在基因集”的Sorlie分类在我们的队列中揭示了四个不同的亚组（正常样：14%，基底样：20%，erbB2+：22%，管腔样：44%），这与最初的描述一致。四个亚组内基因组分级高但组织病理学分级无统计学差异（P<0.001）。根据erbB2+簇分类的肿瘤中约45.5%显示出病理完全缓解，而正常样亚组为0%，基底样亚组为10.0%，管腔样亚组为9.1%（P=0.024）。与正常样（28.6%）、基底样（30.0%）和管腔样（13.6%）簇相比，erbB2+亚组（0%）的肿瘤复发趋势较低（P=0.215）。我们的数据表明，基于“内在基因集”的分子肿瘤亚型可用于预测NAC后的肿瘤反应。
